Member Info for Agenda101

It must be renamed as : WYN Group Share Chat?

Everytime I take a peek at the board.. The top header is always about Wyn(I’ve blocked him yrs ago)…

I think I’ll unblock..

He is definitely the King Of This Chat Group and he’s been king of this board for years…..

Something to be proud of Wyn, keep up the good work.. I’d certainly pay this guy to disrupt! He’s not that stupid tbh… he’s had all of you furiously frustrated at times…

Keep up the good work and what your paid to do!👍

what more needs to be said. your all as bad as each other.. it’s absolutely shocking..**** board with no content!

We wait…….

Meaning:

“The measured biological signals are showing positive signs that the drug is working as intended”.

Will we see a surge in ISA top ups today?👀

“ leading oncologists are currently reviewing the emerging data and have noted that the results appear to be exceptional. Their early assessments further reinforce the strength and potential significance of these findings, lending additional credibility and optimism as the data continues to be evaluated in greater depth.

Https://www.londonstockexchange.com/news-article/AVCT/first-patient-treated-in-phase-1-trial-of-ava6103/17526769

Despite significant interest in AVA6103, the Company's strategy remains to retain all rights to AVA6103 at least until the Company has sight of the initial results from the Phase 1a trial.

Thanks to Stonks

https://x.com/jstonker/status/2031270617169703402?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Https://x.com/jenkoool/status/2029251745612763522?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Or here

https://avacta.com/events-presentations/46th-annual-td-cowen-health-care-conference-in-boston/

Https://x.com/avacta/status/2029249602637955167?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Thought we were looking fwd to something!

Great RNS.. So bullish!

Big week this week…..

About time. Green binned BV

How long have you been on the board BV???🥴🥴🥴

BV,

“Worth noting FAP is an enzyme, not a receptor. AVA compounds are substrates, not inhibitors. If cleavage rates differ, it’s more likely chemistry or payload-related than ‘occupying’ the cleavage site.”

I will accept that you were not using precise terminology.😂😂

I think it’s helpful to separate a few concepts here. The size of the current anthracycline market reflects long established clinical use rather than the absence of recognised limitations within the class. Those limitations are already well documented and are, in fact, the rationale for developing next-generation approaches such as Faridox.

As a result, positioning Faridox as simply “doing a better job” than existing anthracyclines risks oversimplifying the investment case, which is more about differentiation from the known constraints of the class than a like-for-like comparison.

GLA

I very much remember him saying that!

https://x.com/tom_the_bomb__/status/1631650188141133828?s=46&t=duWTVR3YhEB6IsWdJtkMpQ